Cargando…

Trop2 Expression in Extramammary Paget’s Disease and Normal Skin

Extramammary Paget’s disease (EMPD) is a rare skin cancer arising in the apocrine gland-rich areas. Most EMPD tumors are dormant, but metastatic lesions are associated with poor outcomes owing to the lack of effective systemic therapies. Trophoblast cell surface antigen 2 (Trop2), a surface glycopro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Takamichi, Tanegashima, Keiko, Tanaka, Yuka, Hashimoto, Hiroki, Murata, Maho, Oda, Yoshinao, Kaku-Ito, Yumiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304908/
https://www.ncbi.nlm.nih.gov/pubmed/34299325
http://dx.doi.org/10.3390/ijms22147706
_version_ 1783727447679696896
author Ito, Takamichi
Tanegashima, Keiko
Tanaka, Yuka
Hashimoto, Hiroki
Murata, Maho
Oda, Yoshinao
Kaku-Ito, Yumiko
author_facet Ito, Takamichi
Tanegashima, Keiko
Tanaka, Yuka
Hashimoto, Hiroki
Murata, Maho
Oda, Yoshinao
Kaku-Ito, Yumiko
author_sort Ito, Takamichi
collection PubMed
description Extramammary Paget’s disease (EMPD) is a rare skin cancer arising in the apocrine gland-rich areas. Most EMPD tumors are dormant, but metastatic lesions are associated with poor outcomes owing to the lack of effective systemic therapies. Trophoblast cell surface antigen 2 (Trop2), a surface glycoprotein, has drawn attention as a potential therapeutic target for solid tumors. Sacituzumab govitecan, an antibody–drug conjugate of Trop2, has recently entered clinical use for the treatment of various solid cancers. However, little is known about the role of Trop2 in EMPD. In this study, we immunohistochemically examined Trop2 expression in 116 EMPD tissue samples and 10 normal skin tissues. In normal skin, Trop2 was expressed in the epidermal keratinocytes, inner root sheaths, and infundibulum/isthmus epithelium of hair follicles, eccrine/apocrine glands, and sebaceous glands. Most EMPD tissues exhibited homogeneous and strong Trop2 expression, and high Trop2 expression was significantly associated with worse disease-free survival (p = 0.0343). These results suggest the potential use of Trop2-targeted therapy for EMPD and improve our understanding of the skin-related adverse effects of current Trop2-targeted therapies such as sacituzumab govitecan.
format Online
Article
Text
id pubmed-8304908
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83049082021-07-25 Trop2 Expression in Extramammary Paget’s Disease and Normal Skin Ito, Takamichi Tanegashima, Keiko Tanaka, Yuka Hashimoto, Hiroki Murata, Maho Oda, Yoshinao Kaku-Ito, Yumiko Int J Mol Sci Article Extramammary Paget’s disease (EMPD) is a rare skin cancer arising in the apocrine gland-rich areas. Most EMPD tumors are dormant, but metastatic lesions are associated with poor outcomes owing to the lack of effective systemic therapies. Trophoblast cell surface antigen 2 (Trop2), a surface glycoprotein, has drawn attention as a potential therapeutic target for solid tumors. Sacituzumab govitecan, an antibody–drug conjugate of Trop2, has recently entered clinical use for the treatment of various solid cancers. However, little is known about the role of Trop2 in EMPD. In this study, we immunohistochemically examined Trop2 expression in 116 EMPD tissue samples and 10 normal skin tissues. In normal skin, Trop2 was expressed in the epidermal keratinocytes, inner root sheaths, and infundibulum/isthmus epithelium of hair follicles, eccrine/apocrine glands, and sebaceous glands. Most EMPD tissues exhibited homogeneous and strong Trop2 expression, and high Trop2 expression was significantly associated with worse disease-free survival (p = 0.0343). These results suggest the potential use of Trop2-targeted therapy for EMPD and improve our understanding of the skin-related adverse effects of current Trop2-targeted therapies such as sacituzumab govitecan. MDPI 2021-07-19 /pmc/articles/PMC8304908/ /pubmed/34299325 http://dx.doi.org/10.3390/ijms22147706 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ito, Takamichi
Tanegashima, Keiko
Tanaka, Yuka
Hashimoto, Hiroki
Murata, Maho
Oda, Yoshinao
Kaku-Ito, Yumiko
Trop2 Expression in Extramammary Paget’s Disease and Normal Skin
title Trop2 Expression in Extramammary Paget’s Disease and Normal Skin
title_full Trop2 Expression in Extramammary Paget’s Disease and Normal Skin
title_fullStr Trop2 Expression in Extramammary Paget’s Disease and Normal Skin
title_full_unstemmed Trop2 Expression in Extramammary Paget’s Disease and Normal Skin
title_short Trop2 Expression in Extramammary Paget’s Disease and Normal Skin
title_sort trop2 expression in extramammary paget’s disease and normal skin
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304908/
https://www.ncbi.nlm.nih.gov/pubmed/34299325
http://dx.doi.org/10.3390/ijms22147706
work_keys_str_mv AT itotakamichi trop2expressioninextramammarypagetsdiseaseandnormalskin
AT tanegashimakeiko trop2expressioninextramammarypagetsdiseaseandnormalskin
AT tanakayuka trop2expressioninextramammarypagetsdiseaseandnormalskin
AT hashimotohiroki trop2expressioninextramammarypagetsdiseaseandnormalskin
AT muratamaho trop2expressioninextramammarypagetsdiseaseandnormalskin
AT odayoshinao trop2expressioninextramammarypagetsdiseaseandnormalskin
AT kakuitoyumiko trop2expressioninextramammarypagetsdiseaseandnormalskin